A recombinant DNA and vaccinia virus prime–boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice
- 12 February 2009
- Vol. 27 (15) , 2085-2088
- https://doi.org/10.1016/j.vaccine.2009.02.003
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform “Spotty Business”Journal of Virology, 2008
- Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c miceHepatology, 2007
- Recombinant adeno-associated virus vectors induce functionally impaired transgene product–specific CD8+ T cells in miceJournal of Clinical Investigation, 2007
- Development of a heterologous, multigenotype vaccine against hepatitis C virus infectionEuropean Journal of Clinical Investigation, 2007
- Flying Under the Radar: The Immunobiology of Hepatitis CAnnual Review of Immunology, 2007
- Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleJournal of Virology, 2006
- Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee†Hepatology, 2005
- A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman PrimatesJournal of Virology, 2005
- Immunology of hepatitis B virus and hepatitis C virus infectionNature Reviews Immunology, 2005
- A DNA vaccine containing inverted terminal repeats from adeno‐associated virus increases immunity to HIVThe Journal of Gene Medicine, 2002